autologous tumor infiltrating lymphocytes HV-101

A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patient's resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, autologous TILs HV-101 specifically recognize and kill the patient's tumor cells.